In situ modeling of acquired resistance to RTK/RAS pathway targeted therapies

Nancy E. Sealover(Uniformed Services University of the Health Sciences), Robert L. Kortum(Uniformed Services University of the Health Sciences)
bioRxiv (Cold Spring Harbor Laboratory)
January 28, 2023
10.1101/2023.01.27.525958
Cited by 2

Related Papers

A Phospholipase C-γ1–Independent, RasGRP1-ERK–Dependent Pathway Drives Lymphoproliferative Disease in Linker for Activation of T Cells–Y136F Mutant Mice
|The Journal of Immunology|2012|17
In situ modeling of acquired resistance to RTK/RAS-pathway-targeted therapies
|iScience|2023|14
Wild-type RAS signaling is an essential therapeutic target in <i>RAS</i> -mutated cancers
|Science Signaling|2025|3
SOS1 inhibition suppresses the emergence of osimertinib resistance to generate a durable response in <i>EGFR</i> -mutant lung cancer
|Science Signaling|2025|2